Although data presented here solidly confirm that ER-positive/HER2-negative/luminal breast cancers with high and low tumor mutation numbers have similar prognoses, they do not inform regarding total tumor mutation numbers as predictive markers of immunotherapy response, as the patients in the series examined did not receive immunotherapies. The gene discussed is ESR1; the disease is neoplasm.